Ocular Therapeutix CEO Pravin Dugel confirmed the company is on schedule to file the New Drug Application (NDA) for AXPAXLI in the fourth quarter of 2026. The company recently had a successful pre-NDA meeting with the FDA in Q3, receiving positive feedback that boosts confidence in the upcoming filing. This regulatory milestone is key for advancing AXPAXLI toward potential approval and market entry. Investors should watch for the NDA submission as a critical event for the company’s progress in retinal treatment development.
Ocular Therapeutix's regulatory progress on AXPAXLI NDA filing provides context for the health sector's market snapshot on Pluang as of Oct 24, 2026 03:11 WIB. Among 150 priced health-sector US stocks, 62 rose and 88 fell. Notably, CTXR gained 7.87% with 98% of Pluang orders buying and a typical hold time of 18 days, contrasting with ABCL which dropped 7.27% despite 88% buy orders and a longer hold time of 41 days. LQDA also rose 7.61% but saw a more balanced order activity of 44% sell and 56% buy with a short hold time of 2 days.
Remittix has raised $33 million and will burn 300 million RTX tokens, reducing supply by 20% ahead of public trading starting November 24, 2026. This token burn and near-cap funding boost scarcity and investor interest. Meanwhile, the XRP Ledger's No...
XTransfer, a leading global B2B cross-border payment platform, made its first appearance at Money20/20 USA 2026 in Las Vegas to accelerate its expansion into Latin American markets. The company recently completed regulatory registration in Chile, ena...
Kelvin Veras Real Estate completed 16 real estate transactions in its first year operating in New Jersey, including sales, purchases, rentals, and landlord services. This milestone highlights the company's successful market entry and diverse client s...
The documentary 'NURSE: Empathy Heals' premiered on October 21 in Nashville, showcasing personal stories of nurses and the critical role of empathy in healthcare. It highlights the emotional challenges nurses face, especially during crises like the C...
Oxford Square Capital Corp. announced it will hold a conference call on October 30, 2026, at 9:00 AM Eastern time to discuss its third quarter 2026 earnings. Investors can join the call via a toll-free number, and a recorded replay will be available ...
